Entrepreneur
WHIS USA 2026 announces first ticket release for landmark Women’s Health Innovation Summit
WHIS, the premier event uniting the global women’s health and healthcare innovation ecosystem, has officially launched its first ticket release for the 2026 summit, taking place October 13–15, 2026 at Encore Boston Harbor.
Bringing together leaders from across healthcare, life sciences, technology, investment and policy, WHIS returns for its 8th year as a critical platform for collaboration, insight sharing, and accelerating progress in women’s health innovation.
The 2026 agenda will be structured around four key content tracks designed to address the most pressing challenges and opportunities across the ecosystem:
- Healthcare Costs & Models
- Consumer-Centric Care
- AI & Digital Health
- Discovery, Development & Commercialisation
These tracks reflect the full lifecycle of healthcare innovation, from early-stage research and development through to patient delivery, system transformation, and commercial scale.
Attendees can expect a dynamic, multi-day programme featuring high-impact keynotes, expert-led panels, interactive sessions, and curated networking opportunities.
The event will convene innovators, investors, policymakers, healthcare providers, payers, and industry partners to co-create solutions that improve outcomes and address persistent gaps in care.
First Release Tickets Now Available – Lowest Price Ever
WHIS has also announced that its first ticket drop is now live, offering the lowest ticket price ever released for the event.
This initiative reflects a commitment to making the summit more accessible to a broader cross-section of the healthcare community.
However, ticket availability is strictly limited, and early demand is expected to be high.
“We are focused on opening up access to the conversations and connections that truly drive change in women’s health,” said Poppy Howard-Wall, lead conference producer.
“By offering our lowest-ever ticket pricing in this first release, we’re ensuring that innovators, startups, and emerging leaders can be part of shaping the future of healthcare.”
WHIS builds on its legacy of cross-sector collaboration and driving scalable innovation across the industry.
For more information visit: whisusa.com
Five women-led startups will compete for a share of a £30,000 prize fund in Imperial’s WE Innovate final on Monday 15 June 2026.
The finalists are building businesses to tackle challenges in areas including vaccine technology, epilepsy care and the destruction of “forever chemicals”.
The WE Innovate programme, run by Imperial Enterprise Lab, is a targeted pre-accelerator open to teams led by students, recent alumni and early career researchers who identify as women.
The programme supports 25 women-led teams through six months of masterclasses, business coaching, one-to-one expert support and peer mentoring.
The top five teams will compete to win a share of the £30,000 prize fund at the WE Innovate Grand Final Showcase at Imperial on Monday 15 June 2026 from 18:00 to 21:00.
Tickets are free and available on a first-come, first-served basis.
This year’s final also marks the second year of WE Innovate National, a growing UK-wide programme that has expanded the WE Innovate model built at Imperial to other parts of the country.
Alongside Imperial, Queen’s University Belfast, Swansea University and Loughborough University are each hosting their own grand final showcases on their campuses.
The four showcases are collectively contributing to a shared national ecosystem focused on supporting women-led innovation.
WE Innovate National is set to expand to seven universities next year, supporting 175 women-led startup teams across the UK.
AlphaVectors Biotech is developing a lipid nanoparticle platform to enhance the stability of RNA vaccines at room temperatures.
Lipid nanoparticles are tiny fat-based particles used to deliver genetic medicines into the body. RNA vaccines use genetic instructions to help the immune system recognise a disease target.
Current RNA-based therapeutics rely on lipid nanoparticles that need storage at between -20°C and -80°C and high dosing. This increases distribution costs and leads to significant wastage, limiting scalability, deployment and accessibility in lower-resource markets.
AlphaVectors Biotech says its technology can lower the need for temperature-controlled supply chains, reduce costs and improve the scalability of RNA vaccines for wider deployment.
The startup is led by Dr Apanpreet Kaur, an Imperial alumnus with a PhD in chemical engineering.
Epile-X, by NeuraVance Labs, is working on a platform that could provide continuous, real-world brain monitoring for people with epilepsy.
More than 630,000 people in the UK live with epilepsy, according to the charity Epilepsy Action.
Epilepsy is a neurological condition that can cause recurring seizures. EEG, or electroencephalography, is a test that records electrical activity in the brain.
Current diagnosis relies on EEG recordings in clinical settings and patient-reported diaries, which may miss seizures that happen during daily life.
The startup says its technology combines a wearable EEG with AI-driven analysis to capture daily brain activity and support improved diagnosis and more personalised treatment decisions.
Epile-X is led by Ester D’Alterio, an innovation, entrepreneurship and management MSc graduate from Imperial.
FluoroCycle is developing technology for low-energy chemical destruction of PFAS, breaking down “forever chemicals” at 10 times lower temperatures than current incineration methods.
PFAS are synthetic chemicals found in air, water and soil. Some studies have linked exposure to them to health risks including thyroid disease, reproductive illness and cancer.
The startup aims to make PFAS destruction more affordable by providing its technology as an onsite engineered unit, allowing customers to save on energy and transport costs while cutting their carbon footprint.
FluoroCycle is led by Amanda Fogh, a research associate in Imperial’s department of chemistry.
Waypoint is building a video game controller for visually impaired players to hear and feel popular games, including Super Mario and Minecraft.
At least 2.2 billion people globally have some form of vision impairment, according to the World Health Organisation, while estimates show around 43 million people have complete blindness.
Waypoint says only 0.001 per cent of video games are fully playable for blind gamers.
The startup’s technology uses computer vision and AI to read the game screen and translate key information into sound, vibration and touch for a fully immersive experience.
The founders say it is the first game controller designed to make video games fully playable for blind players.
Waypoint is led by Bana Quronfuleh, an innovation design engineering MSc student at Imperial.
Snitch is developing an accountability-based app that allows friends to cut down their screen time together.
UK adults spend an average of 4.5 hours a day online on personal smartphones, tablets and computers, according to Ofcom’s Online Nation 2025 report.
Young adults spend more than six hours online on average. Some research suggests excessive screen use may have a negative impact on mental and physical health.
The app allows users to join accountability groups and set shared limits across their most used apps.
When one person scrolls, the group’s combined timer counts down. The founders say this helps build awareness, encourage reflection and create small behavioural shifts by making screen use a shared responsibility.
Snitch is led by Asha Bakhai, a design engineering MEng graduate from Imperial.
Indian pharmaceutical giant Sun Pharma has agreed to buy Organon for US$11.75bn in a deal aimed at expanding its women’s health and biosimilars business.
Organon, which was spun out of Merck in 2021, has built a portfolio of more than 70 women’s health and general medicines products, including biosimilars, sold in the US and about 140 other countries.
The acquisition would give Sun Pharma a broader presence in biosimilars, which are medicines designed to be highly similar to existing biological drugs, and strengthen its position in women’s health.
Dilip Shanghvi, executive chairman of Sun Pharma, said: “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”
The companies said the combined business would generate annual revenue of US$12.4bn, operate across 150 countries and rank among the top three companies globally in women’s health.
They also said it would become the seventh largest biosimilar player.
Sun Pharma said the deal would help grow its innovative medicines business and expand its biosimilars offering.
It added that the combined company would have 18 large markets each generating more than US$100m in revenue.
Organon’s largest markets include the US, Brazil, Canada, China and countries in the European Union. The company also has six manufacturing facilities across the EU and emerging markets.
The deal follows market speculation that began on 10 April, when Indian media reported that Sun Pharma had submitted an all-cash offer for Organon.
A later report said the offer had been revised to US$13bn. Sun Pharma shares rose about 7 per cent on India’s National Stock Exchange after the announcement.
Sun Pharma said it would acquire all of Organon’s issued and outstanding shares in cash, using a combination of available cash and committed bank financing. It also estimated synergies of about US$350m within two to four years of completion.
The company said the acquisition would strengthen its cash generation, with EBITDA and cash flow set to nearly double, supporting efforts to reduce the net debt to EBITDA ratio of 2.3 times resulting from the deal. EBITDA is a measure of operating performance before certain costs are deducted.
Organon reported revenue of US$6.2bn last year and adjusted EBITDA of US$1.9bn. It also reported debt of US$8.64bn, down from US$9.5bn when it separated from Merck, and a cash balance of US$574m.
In November, Organon announced plans to sell its JADA System, designed to control and treat abnormal postpartum uterine bleeding or haemorrhage, to Laborie Medical Technologies for up to US$465m. Net proceeds from the sale will contribute to Organon’s cash balance as of 31 March 2026.
Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The boards of both companies have approved the transaction.
Carrie Cox, executive chair of Organon, said: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”
The transaction is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.
The women’s digital health market is set to reach US$5.28bn in 2026, up from US$4.36bn in 2025, according to a new report.
That would represent annual growth of 20.9 per cent, driven by factors including greater smartphone use among women, wider uptake of telehealth and a stronger focus on preventive care.
The report said the market could reach US$11.47bn by 2030, with projected annual growth of 21.4 per cent over the forecast period.
It also pointed to rising awareness of gender-specific health needs, expansion among digital health start-ups, growing demand for personalised healthcare, investment in femtech innovation and the spread of AI-enabled diagnostics.
Wearables linked to health apps and wider use of remote monitoring tools are also expected to play a larger role, as companies focus on more preventive and joined-up care.
Smartphone use was highlighted as a major driver because mobile apps are increasingly being used for women’s health services, from menstrual cycle tracking to pregnancy support.
The report cited Eurostat data showing that in 2023, 89 per cent of EU residents aged 16 to 74 in urban areas accessed the internet via smartphones.
The report also said companies in the sector are developing new technology aimed at improving access to more personalised healthcare.
One example it gave was a 2024 collaboration between Algorand and the Self-Employed Women’s Association to launch a digital health passport for women in India’s informal economy using blockchain technology.
Recent mergers and acquisitions were also noted. In March 2023, Maven Clinic acquired Naytal to expand its services in the UK and Europe.
North America was identified as the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region.
Companies named as key players included Flo Health Inc, Natural Cycles, Elvie, Bellabeat, Clue by Biowink, MobileODT Ltd., Glow, Veera Health, Biowink GmbH, Ava AG, Hims & Hers Health, Inc., The Women’s Wellness Centre, Elara Health, myGynaeDoc, Maven Clinic, Kindbody, Allara Health, Tia and Hera Med Ltd.
News4 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Fertility4 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Wellness3 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Opinion3 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Fertility4 weeks agoToxins and climate harms having ‘alarming’ effect on fertility, research warns
News2 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Adolescent health2 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Fertility4 weeks agoResearcher explores weight loss jab impact on PCOS